[go: up one dir, main page]

WO2013008253A3 - Imatinib formulations - Google Patents

Imatinib formulations Download PDF

Info

Publication number
WO2013008253A3
WO2013008253A3 PCT/IN2012/000488 IN2012000488W WO2013008253A3 WO 2013008253 A3 WO2013008253 A3 WO 2013008253A3 IN 2012000488 W IN2012000488 W IN 2012000488W WO 2013008253 A3 WO2013008253 A3 WO 2013008253A3
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
salts
pharmaceutical formulations
formulations
relate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000488
Other languages
French (fr)
Other versions
WO2013008253A2 (en
Inventor
Suresh KONATHAM
Madhusudan MALLADI
Prasad Vure
Moumita BISWAS
Rahul BHISE
Ramesh KOTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Priority to IN1009CHN2014 priority Critical patent/IN2014CN01009A/en
Publication of WO2013008253A2 publication Critical patent/WO2013008253A2/en
Publication of WO2013008253A3 publication Critical patent/WO2013008253A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Aspects of the present application relate to pharmaceutical formulations comprising imatinib or its salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, and polymorphs, and mixtures thereof. Further aspects relate to processes for preparing pharmaceutical formulations comprising imatinib or its salts, together with at least one pharmaceutically acceptable excipient.
PCT/IN2012/000488 2011-07-11 2012-07-11 Imatinib formulations Ceased WO2013008253A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1009CHN2014 IN2014CN01009A (en) 2011-07-11 2012-07-11

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506191P 2011-07-11 2011-07-11
US61/506,191 2011-07-11

Publications (2)

Publication Number Publication Date
WO2013008253A2 WO2013008253A2 (en) 2013-01-17
WO2013008253A3 true WO2013008253A3 (en) 2013-03-07

Family

ID=47506639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000488 Ceased WO2013008253A2 (en) 2011-07-11 2012-07-11 Imatinib formulations

Country Status (1)

Country Link
WO (1) WO2013008253A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
EP2803353B1 (en) * 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
BR112022000571A2 (en) * 2019-07-15 2022-03-15 Intas Pharmaceuticals Ltd Pharmaceutical composition and process for preparing a pharmaceutical composition comprising imatinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients in powder form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
WO2008027600A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
WO2008027600A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NONYMOUSLY, D.: "Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM, 19 February 2008 (2008-02-19) *
VASANTHAVADA, M. ET AL.: "Application of Melt Granulation Technology Using Twin-screw Extruder in Development of High-dose Modified-release Tablet Formulation", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 5, May 2011 (2011-05-01), pages 1923 - 1934 *

Also Published As

Publication number Publication date
WO2013008253A2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
WO2012103226A3 (en) Bendamustine formulations
IN2014MN02598A (en)
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
CR20150114A (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
WO2014041565A3 (en) Improved process for preparation of vilanterol and intermediates thereof
PH12015500376B1 (en) Novel bicyclic pyridinones
IN2015DN00845A (en)
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
WO2014062838A3 (en) Pkm2 modulators and methods for their use
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
PH12015502477A1 (en) Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione
WO2013008253A3 (en) Imatinib formulations
WO2011023954A3 (en) Polymorphic forms of manidipine
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2013008269A (en) Pharmaceutical composition comprising pyridone derivatives.
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
MX2013009386A (en) New azaspirodecanone compounds.
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
IN2013MU03308A (en)
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2012139074A3 (en) Migrastatins and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12810770

Country of ref document: EP

Kind code of ref document: A2